MedTrace Logo

Imaging of Vesicular Acetylcholine and Dopamine Transporters in Dementia With Lewy Bodies

NCT00917709 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2026-05-14

No results posted yet for this study

Summary

The general aim of this research project is to determine the relationships between alterations of central cholinergic (ACh) and dopaminergic (DA) systems and neurobehavioral features of dementias with Lewy bodies (DLB).

Both clinical and neurochemical data support the view that DLB is not a homogeneous entity and it can be hypothesized that differential alterations of central ACh systems (i.e. anterior vs posterior vs striatal interneurons) in association or not with a DA nigrostriatal dysfunction could partly support the clinical heterogeneity observed in this disease. ACh in vivo imaging has been relatively underutilized to date and to our knowledge only on the postsynaptic side. Furthermore, ACh/DA interactions and their relationships with the symptomatology of DLB and related pathologies (PDD) had never been investigated.

Conditions

Interventions

OTHER

Imaging with IBVM

in vivo molecular imaging of presynaptic molecular target of cholinergic systems with \[123I\]-iodobenzovesamicol

OTHER

Imaging with DATSCAN

in vivo molecular imaging of presynaptic molecular target of dopaminergic systems (DAT) with DATSCAN

BEHAVIORAL

neuropsychological evaluation

neuropsychological evaluation using neuropsychological tests

Sponsors & Collaborators

  • University Hospital, Bordeaux

    lead OTHER

Principal Investigators

  • Michèle ALLARD, Pr · University Hospital, Bordeaux

Study Design

Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2013-09-30
Completion
2013-10-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00917709 on ClinicalTrials.gov